Enzymatic conjugation of antibodies

CPC - классификация

AA6A61A61KA61K4A61K47A61K47/A61K47/4A61K47/48A61K47/482A61K47/4821A61K47/48215A61K47/483A61K47/4836A61K47/48369A61K47/4838A61K47/48384A61K47/486A61K47/4862A61K47/48623A61K47/4864A61K47/48646A61K47/6A61K47/60A61K47/68A61K47/680A61K47/6803A61K47/68031A61K47/6807A61K47/681A61K47/6813A61K47/6817A61K47/686A61K47/6865A61K47/687A61K47/6871A61PA61P3A61P35A61P35/A61P35/0A61P35/00CC0C07C07CC07C2C07C21C07C217C07C217/C07C217/0C07C217/08C07C22C07C223C07C223/C07C223/0C07C223/02C07C229C07C229/C07C229/2C07C229/26C07C23C07C233C07C233/C07C233/6C07C233/62C07C24C07C247C07C247/C07C247/0C07C247/04C07C3C07C32C07C323C07C323/C07C323/1C07C323/12C07C323/6C07C323/60C07DC07D2C07D22C07D225C07D225/C07D225/0C07D225/08C07D25C07D257C07D257/C07D257/0C07D257/08C07D27C07D277C07D277/C07D277/0C07D277/06C07FC07F9C07F9/C07F9/5C07F9/50C07F9/502C07F9/5022C07KC07K1C07K16C07K16/C07K16/0C07K16/00C07K19C07K19/C07K19/0C07K19/00C07K2C07K23C07K231C07K2317C07K2317/C07K2317/4C07K2317/40C1C12C12NC12N9C12N9/C12N9/1C12N9/10C12N9/104C12N9/1044C12PC12P2C12P21C12P21/C12P21/0C12P21/00C12P21/005GG0G01G01NG01N3G01N33G01N33/G01N33/6G01N33/68G01N33/685G01N33/6854

IPC - классификация

AA6A61A61PA61P3A61P35A61P35/A61P35/0A61P35/00A61P35/02A61P35/04CC0C07C07CC07C2C07C21C07C217C07C217/C07C217/0C07C217/08C07C22C07C223C07C223/C07C223/0C07C223/02C07C229C07C229/C07C229/2C07C229/26C07C23C07C233C07C233/C07C233/6C07C233/62C07C24C07C247C07C247/C07C247/0C07C247/04C07C3C07C32C07C323C07C323/C07C323/1C07C323/12C07C323/6C07C323/60C07DC07D2C07D22C07D225C07D225/C07D225/0C07D225/08C07D25C07D257C07D257/C07D257/0C07D257/08C07D27C07D277C07D277/C07D277/0C07D277/06C07FC07F9C07F9/C07F9/5C07F9/50C07KC07K1C07K16C07K16/C07K16/0C07K16/00C07K16/1C07K16/18C07K16/2C07K16/22C07K16/28C07K16/3C07K16/30C07K19C07K19/C07K19/0C07K19/00C1C12C12NC12N9C12N9/C12N9/1C12N9/10C12PC12P2C12P21C12P21/C12P21/0C12P21/00GG0G01G01NG01N3G01N33G01N33/G01N33/6G01N33/68

Цитирование НПИ

Agard et al., J Am Chem Sco 126: 15045-15047, 2004.
Altschul et al., Basic Local Alignment Search Tool. J Mol Biol. (1990) 215:403-410.
Altschul et al., Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs. Nucleic Acids Res. (1997) 25:3389-3402.
Amersham Biosciences, Antibody Purification Handbook, (2002) Publication No. 18-1037-46, Edition AC, 112 pages.
Amsberry et al., The Lactonization of 2′-Hydroxyhydrocinnamic Acid Amides: A Potential Prodrug for Amines. J Org Chem. (1990) 55:5867-5877.
Ando et al., Purification and Characteristics of a Novel Transglutaminase Derived from Microorganisms. Agric Biol Chem. (1989) 53(10):2613-2617.
Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing and Wiley-Interscience, (1993) [TOC only].
Baeuerle et al., “Bispecific T-cell engaging antibodies for cancer therapy”, Cancer Res. (2009) 69(12):4941-4944.
Bernhard et al., “Cysteine analogs of recombinant barley ribosome inactivating protein form antibody conjugates with enhanced stability and potency in vitro”, Bioconjugate Chem., (1994) 5(2):126-132.
Brabez et al., Design, Synthesis, and Biological Studies of Efficient Multivalent Melanotropin Ligands: Tools Towards Melanoma Diagnosis and Treatment. J Med Chem. (2011) 54(20):7375-7384.
Carrillo et al., The Multiple Sequence Alignment Problem in Biology. Siam J Appl Math. (1988) 48(5):1073-1082.
Carter et al., Humanization of an Anti-P185HER2 Antibody for Human Cancer Therapy. Proc Natl Acad Sci. USA (1992) 89:4285-4289.
Carter et al., Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors. Nucleic Acids Res. (1985) 13(12):4431-4443.
Chapman, Andrew P., PEGylated Antibodies and Antibody Fragments for Improved Therapy: A Review. Adv Drug Del Rev. (2002) 54:531-545.
Chari, Ravi V.J., “Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs”, Acc of Chem Res. (Jan. 2008) 41(1):98-107.
Chothia et al., Canonical Structures for the Hypervariable Regions of Immunoglobulins. J Mol Biol. (1987) 196:901-917.
Connolly et al., “In Vivo Inhibition of Fas Ligand-Mediated Killing by TR6, a Fas Ligand Decoy Receptor”, J Pharmacol Exp Ther. (2001) 298(1):25-33.
De Pascalis et al., Grafting of “Abbreviated” Complementarity-determining Regions Containing Specificity-determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody. J Immunol. (2002) 169:3076-3084.
Dennler et al., Enzymatic antibody modification by bacterial transglutaminase. Bioconjugate Chemistry, (2013) 1045:205-215.
Dennler et al., ransglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjugate Chemistry, (2014) 25(3):569-578.
Devereux et al., A Comprehensive Set of Sequence Analysis Programs for the VAX. Nucl Acid Res. (1984) 12(1):387-395.
Doronina et al., Development of Potent Monoclonal Antibody Auristatin Conjugates for Cancer Therapy. Nature Biotech. (2003) 21(7):778-784.
Doronina et al., “Enhanced activity of monomethylauristatin F through Monoclonal Antibody Delivery”, Bioconjugate Chem. (2006) 17(1):114-124.
Dosio et al., “Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components”, Toxins (2011) 3:848-883.
Edelman et al., The Covalent Structure of an Entire γGimmunoglobulin Molecule. The Rockefeller University (1969) 63:78-85.
Folk et al , “Polyamines as Physiological Substrates for Transglutaminases”, The Journal of Biological Chemistry, vol. 255, No. 8, Issue of Apr. 25, pp. 3695-3700, 1980.
Folk et al., Polyamines as Physiological Substrates for Transglutaminases. J Biol Chem. (1980) 255(8):3695-3700.
Genbank Reference Sequence NM—024003.2; “Homo sapiens L1 cell adhesion molecule (L1CAM), transcript variant 2, mRNA”, May 4, 2013; 8 pages.
Genbank Reference Sequence NM—024003.3; “Homo sapiens L1 cell adhesion molecule (L1CAM), transcript variant 2, mRNA”, May 26, 2013; 10 pages.
Genbank Reference Sequence NM—076493.1; “Neural cell adhesion molecule L1 isoform 2 precursor [Homo sapiens]”, May 26, 2014; 6 pages.
Golay et al., “Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays”, Arch Biochem Biophys (2012) 526:146-153.
Gorman et al., Transglutaminase Amine Substrates for Photochemical Labeling and Cleavable Cross-linking of Proteins. J Biol Chem. (1980) 255(3):1175-1180.
Green, et al., Antigen-specific Human Monoclonal Antibodies from Mice Engineered with Human Ig Heavy and Light Chain YACs. Nat Genet. (1994) 7:13-21.
Gregson et al., “Linker Length Modules DNA Cross-Linking Reactivity and Cytotoxic Potency of C8/C8′ Ether-linked C2-exo-Unsaturated Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers”, J Med Chem (2004) 47:1161-1174.
Gribskov et al., (Eds.) Sequence Analysis Primer; Stockton Press (1991); Table of Contents, 7 pages.
Griffin et al., (Eds.) Methods in Molecular Biology-24: Computer Analysis of Sequence Data; Part I & II; Tables of Contents, 8 pages.
Griffiths et al., Human Anti-self Antibodies with High Specificity From Phage Display Libraries. EMBO J. (1993) 12(2):725-734.
Griffiths et al., Isolation of High Affinity Human Antibodies Directly From Large Synthetic Repertoires. The EMBO J. (1994) 13(14):3245-3260.
Grünberg et al. 2013. DOTA-functionalized polylysine: A high No. of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl. PLOS ONE, 8(4):e60350.
Hamblett et al., Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate. Clin Canc Res. (2004) 10:7063-7070.
Harlow et al., (Eds.), Antibodies—A Laboratory Manual; Table of Contents, 9 pages.
Hay et al., A 2-Nitroimidazole Carbamate Prodrug of 5-Amino-1-(Chloromethyl)-3-[(5,6,7-Trimethoxyindol-2-YL)Carbonyl]-1,2-Dihydro-3H-Benz[e]indole (Amino-SECO-CBI-TMI) for Use with ADEPT and GDEPT. Bioorg Med Chem Lttrs. (1999) 9:2237-2242.
Hay et al., “Clinical development success rates for investigational drugs”, Nat Biotech. (Jan. 2014) 32(1):40-51.
Higuchi, Russell “Recombinant PCR” Chapter 22 in Part II of PCR Protocols, A Guide to Methods and Applications [Innis et al. (Eds.)], Academic Press, (1990) pp. 177-183.
Ho et al. Site-directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction. Gene (1989) 77(1):51-59.
Holliger et al., Engineered Antibody Fragments and the Rise of Single Domains. Nat Biotech. (2005) 23(9):1126-1136.
Hu et al., “Rational design of transglutaminase substrate peptides for rapid enzymatic formation of hydrogels”, J Am Chem Soc. (Nov. 2003) 125(47):14298-14299.
Ill et al., Design and Construction of a Hybrid Immunoglobulin Domain with Properties of Both Heavy and Light Chain Variables. Protein Eng. (1997) 10(8):949-957.
International Search Report and Written Opinion mailed Sep. 24, 2014 for International Application No. PCT/EP2014/063064 filed Jun. 20, 2014, 16 pages.
International Search Report and Written Opinion of the International Searching Authority mailed Aug. 20, 2014 for International Application No. PCT/EP2014/063061 filed Jun. 20, 2014.
International Search Report mailed Apr. 15, 2014 for International Application No. PCT/EP2013/073428 filed Nov. 8, 2013.
International Search Report mailed Apr. 23, 2013 for International Application No. PCT/EP2012/076631 filed Dec. 21, 2012.
International Search Report mailed Feb. 5, 2014 for International Application No. PCT/EP2012/076606 filed Dec. 21, 2012.
International Search Report mailed Jan. 31, 2014 for International Application No. PCT/EP2013/064605 filed Jul. 10, 2013.
International Search Report mailed Jun. 25, 2014 for International Application No. PCT/EP2014/055140 filed Mar. 14, 2014.
Ito et al A General Method for Introducing a Series of Mutations into Cloned DNA Using the Polymerase Chain Reaction. Gene (1991) 102(1):67-70.
Jackman et al., “Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling”, J Biol Chem. (2010) 285(27):20850-20859.
Jakobovits et al., Germ-Line Transmission and Expression of a Human-derived Yeast Artificial Chromosome. Nature (1993) 362:255-258.
Jeffrey et al., “Development and Properties of beta-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates”, Bioconj Chem. (2006) 17:831-840.
Jeger et al., Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase. Angew Chem Int Ed. (2010) 49:9995-9997.
Jeger et al., “Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase”, Supporting Information. Angewandte Chemie International Edition, Wiley VCH, (2010) 49(51): 46 pages.
Jeger. Site-Specific Conjugation of Tumour-Targeting Antibodies Using Transglutaminase. Dissertation. ETH Zurich: University of Basel (2009) 1-135.
Jones et al., Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse. Nature (1986) 321:522-525.
Josten et al., Use of Microbial Transglutaminase for the Enzymatic Biotinylation of Antibodies. J Immunol Methods (2000) 240:47-54.
Jubala et al., “CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma”, Vet Pathol. (2005) 42:368-476.
Junutula et al., Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index. Nat Biotech. (2008) 26(8):925-932.
Kabat et al., (Eds.) Sequences of Proteins of Immunological Interest, 5th Edition; (1991) Table of Contents; 11 pages.
Kajiwara et al., Expression of L1 Cell Adhesion Molecule and Morphologic Features at the Invasive Front of Colorectal Cancer. Am J Clin Pathol. (2011) 136:138-144.
Kamal et al., “Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing ‘click’ chemistry: DNA-binding affinity and anticancer activity”, Bioorg Med Chem Lett. (Feb. 2008) 18(4):1468-1473.
Kamiya et al., Site-specific Cross-linking of Functional Proteins by Transglutamination. Enz Microb Tech. (2003) 33:492-496.
Kamiya et al., “S-Peptide as a Potent Peptidyl Linker for Protein Cross-Linking by Microbial Transglutaminase from Streptomyces mobaraensis”, Bioconj Chem. (2003) 14:351-357.
Kingsbury et al., A Novel Peptide Delivery System Involving Peptidase Activated Prodrugs as Antimicrobial Agents; Synthesis and Biological Activity or Peptidyl Derivatives of 5-Fluorouracil. J Med Chem. (1984) 27:1447-1451.
Knappik et al., Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides. J Mol Biol. (2000) 296:57-86.
Knogler et al., Copper-67 Radioimmunotherapy and Growth Inhibition by Anti-L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis. Clin Cancer Res. (2007) 13(2):603-611.
Kuil et al., ITAM-derived Phosphopeptide-containing Dendrimers as Multivalent Ligands for Syk Tandem SH2 Domain. Org Bio Chem. (2009) 7:4088-4094.
Kunkel, Thomas A., Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection. Proc Natl Acad Sci USA (1985) 82:488-492.
Kämpfer et al., A Numerical Classification of the Genera Streptomyces and Streptoyerticillium Using Miniaturized Physiological Tests. J Gen Microbiol, (1991) 137:1831-1891.
Lesk, Arthur M. (Ed.) Computational Molecular Biology, Oxford University Press (1988); Table of Contents; 4 pages.
Lhospice et al., “Cite-specific conjugation of monomethyl auristatin E to Anti-CD30 antibodies improves their pharmacokinetics and therapeutic index in rodent models”, Mol Pharmaceutics (2015) 12:1863-1871.
Lin et al. Transglutaminase-catalyzed Site-specific Conjugation of Small-molecule Probes to Proteins in vitro and on the Surface of Living Cells. J Am Chem Soc. (2006) 128(14):4542-4543 [Author's manuscript—7 pages].
Liu et al., Identification of Active Site Residues in the “GyrA” Half of Yeast DNA Topoisomerase II. J Bio Chem. (1998) 273(32):20252-20260.
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Nature (1994) 368:856-859.
Lonberg, Nils, Human Antibodies from Transgenic Animals. Nat Biotechnol. (2005) 23(9):1117-1125.
Lorand et al., Specificity of Guinea Pig Liver Transglutaminase for Amine Substrates. Biochem. (1979) 18(9):1756-1765.
Lorand et al., Transglutaminases: Crosslinking Enzymes with Pleiotropic Functions. Nat Rev Mol Cell Biol. (2003) 4:140-156.
Lyon et al., Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues. Meth Enzym. (2012) 502:123-138.
Maeda et al., Susceptibility of Human T-Cell Leukemia Virus Type I-Infected Cells to Humanized Anti-CD30 Monoclonal Antibodies in vitro and i/ vivo. Cancer Sci. (2010) 101(1):224-230.
McCafferty et al., Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains. Nature (1990) 348:552-554.
Mindt et al., Bioconjugate Chem 19: 271-278, 2008.
Mindt et al., Modification of Different IgG1 Antibodies Glutamine and Lysine Using Bacterial and Human Tissue Transglutaminase. Bioconjug Chem. (2008) 19:271-278.
Morrison et al., Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains. Proc Natl Sci. USA (1984) 81:6851-6855.
Moses et al., “the growing applications of click chemistry”, Chem Soc Rev. (Aug. 2007) 36(8):1249-1262.
Murthy et al., Residue Gln-30 of Human Erythrocyte Anion Transporter is a Prime Site for Reaction with Intrinsic Transglutaminase. J Biol Chem. (1994) 269(36):22907-22911.
Murthy et al., Selectivity in the Post-tTranslational, Transglutaminase-dependent Acylation of Lysine Residues. Biochem. (2009) 48:2654-2660.
Nilsson et al., A synthetic IgG-binding domain based on stapylococcal protein A. Protein Eng. (1987) 1(2):107-113.
Pearson, William R., Rapid and Sensitive Sequence Comparison with FASTP and FASTA. Meth Enzymol. (1990) 183(5):63-98.
Pearson, William R., “Flexible sequence similarity searching with the FASTA3 program package”, Methods Mol Biol. (2000) 132:185-219.
Plagmann et al., “Transglutaminase-catalyzed covalent multimerization of camelidae anti-human TNF single domain antibodies improves neutralizing activity”, J Biotech. (2009) 142:170-178.
Presta et al., Humanization of an Antibody Directed Against IgE. J Immunol. (1993) 151(5):2623-2632.
Presta, Leonard G., Antibody Engineering. Curr Opin Struct Biol. (1992) 2:593-596.
Response to Office Action filed Dec. 8, 2015 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
Response to Office Action filed Feb. 29, 2016 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
Riechmann et al., Reshaping Human Antibodies for Therapy. Nature (1988) 332:323-327.
Rodrigues et al., Synthesis and β-Lactamase-mediated Activation of a Cephalosporin-taxol Prodrug. Chemistry Biology (1995) 2:223-227.
Roguska et al., Humanization of Murine Monoclonal Antibodies Through Variable Domain Resurfacing. Proc Natl Acad Sci. USA (1994) 91:969-973.
Sambrook et al., (Eds.) Molecular Cloning—A Laboratory Manual, [2nd Edition]; Cold Spring Harbor Laboratory Press, NY; (1989) Table of Contents, 30 pages.
Sambrook et al., (Eds.) Molecular Cloning—A Laboratory Manual, [3rd Edition]; vol. 1; Cold Spring Harbor Laboratory Press, NY; (2001); Table of Contents, 18 pages.
Sazinsky et al., Aglycosylated Immunoglobulin G1 Variants Productively Engage Activating Fc Receptors. Proc Natl Acad Sci. USA (2008) 105(51):20167-20172.
Sims et al., A Humanized CD18 Antibody Can Block Function Without Cell Destruction. J Immunol. (1993) 151(4):2296-2308.
Smith, Douglas W. (Ed.), Biocomputing—Informatics and Genome Projects, Academic Press, Inc. (1993) Table of Contents, 7 pages.
Stancovski et al., “Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth”, Proc Natl Acad Sci USA. (Oct. 1991) 88(19):8691-8695.
Starling et al., “In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigen”, Bioconjug Chem. (1992) 3(4):315-322.
Strop et al., “Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates”, Chem Biol. (2013) 20(2):161-167.
Sung et al., “Functional glass surface displaying a glutamyl donor substrate for transglutaminase-mediated protein immobilization”, Biotech J. (2010) (5):456-462.
Suzuki et al., Glycopinion Mini-Review: N-Glycosylation/Deglycosylation as a Mechanism for the Post-Translational Modification/Remodification of Proteins. Glycoconjug J. (1995) 12:183-193.
Takazawa et al., Enzymatic Labeling of a Single Chain Variable Fragment of an Antibody With Alkaline Phosphates by Microbial Transglutaminase. Biotech Engin. (2004) 86(4):399-404.
Tan et al., “Superhumanized” Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28. J Immunol. (2002) 169:1119-1125.
Tomlinson et al., The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops. J Mol Biol. (1992) 227:776-798.
U.S. Appl. No. 61/410,840, filed Nov. 5, 2010.
U.S. Appl. No. 61/553,917, filed Oct. 31, 2011.
U.S. Appl. No. 61/579,908, filed Dec. 23, 2011.
U.S. Appl. No. 61/661,569, filed Jun. 19, 2012.
U.S. Appl. No. 61/671,122, filed Jul. 13, 2012.
U.S. Appl. No. 61/671,128, filed Jul. 13, 2012.
U.S. Appl. No. 61/837,932, filed Jun. 21, 2013.
U.S. Notice of Allowance dated Feb. 8, 2017 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Notice of Allowance dated Jun. 6, 2016 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
U.S. Notice of Allowance dated Mar. 28, 2017 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Office Action dated Apr. 23, 2015 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
U.S. Office Action dated Aug. 13, 2015 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Office Action dated Aug. 17, 2016 in U.S. Appl. No. 14/414,432, filed Jan. 12, 2015.
U.S. Office Action dated Aug. 8, 2016 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Office Action dated Dec. 19, 2014 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Office Action dated Dec. 30, 2015 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Office Action dated Feb. 11, 2016 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
U.S. Office Action dated Feb. 25, 2016 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Office Action dated Feb. 27, 2015 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Office Action dated Feb. 28, 2017 in U.S. Appl. No. 14/441,157, filed May 6, 2015.
U.S. Office Action dated Jul. 5, 2016 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Office Action dated Mar. 28, 2017 in U.S. Appl. No. 14/775,647, filed Sep. 11, 2015.
U.S. Office Action dated Mar. 31, 2017 in U.S. Appl. No. 14/414,432, filed Jan. 12, 2015.
U.S. Office Action dated Mar. 31, 2017 in U.S. Appl. No. 14/898,693, filed Dec. 15, 2015.
U.S. Office Action dated Oct. 8, 2015 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
U.S. Office Action dated Sep. 16, 2015 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Pre-Interview Communication dated Jul. 2, 2015 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
U.S. Preliminary Amendment dated May 3, 2013 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Response dated May 2, 2016 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Response dated Nov. 16, 2015 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Response dated Sep. 1, 2016 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Response to Office Action filed Apr. 26, 2017 in U.S. Appl. No. 14/441,157, filed May 6, 2015.
U.S. Response to Office Action filed Dec. 11, 2015 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Response to Office Action filed May 20, 2015 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
U.S. Response to Office Action filed May 23, 2016 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Response to Office Action filed May 28, 2015 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Response to Office Action filed Nov. 17, 2016 in U.S. Appl. No. 14/414,432, filed Jan. 12, 2015.
U.S. Response to Office Action filed Nov. 9, 2016 in U.S. Appl. No. 13/725,382, filed Dec. 21, 2012.
U.S. Response to Pre-Interview Communication filed Jul. 31, 2015 in U.S. Appl. No. 14/582,040, filed Dec. 23, 2014.
U.S. Rule 312 Amendment dated Apr. 3, 2017 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
U.S. Second Preliminary Amendment dated Feb. 17, 2015 in U.S. Appl. No. 13/883,535, filed May 3, 2013.
Uhlén et al., Complete Sequence of the Staphylococcal Gene Encoding Protein A—A Gene Evolved Through Multiple Duplications. J Biol Chem. (1984) 259(3):1695-1702.
Vallette et al., Construction of Mutant and Chimeric Genes Using the Polymerase Chain Reaction. Nuc Acids Res. (1989) 17(2):723-733.
Verhoeyen et al., Reshaping Human Antibodies: Grafting an Antilysozyme Activity. Science (1988) 239:1534-1536.
Von Heinje, Gunnar [Ed.] “Sequence Analysis in Molecular Biology—Treasure Trove or Trivial Pursuit”, 1987, Academic Press [TOC Only].
Wakankar et al., Analytical Methods for Physicochemical Characterization of Antibody Drug Conjugates. Landes Biosci. (2011) 3(2):161-172.
Ward et al., Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted From Escherichia coli. Nature (1989) 341:544-546.
Wells et al., Cassette Mutagenesis: An Efficient Method for Generation of Multiple Mutations at Defined Sites. Gene (1985) 34(2-3):315-323.
Wängler et al., “Antibody-Dendrimer Conjugates: The Number, Not the Size of the Dendrimers, Determines the Immunoreactivity” Bioconjugate Chem. (2008) (19)4:813-820.
Xu et al., “Characterization of intact antibody drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography mass spectrometry”, Anal Biochem. (2011) 412(1): 56-66.
Yu et al., “Interaction between Bevacizumab and Murine VEGF-A: A Reassessment”, Invest Ophtalmol Vis Sci. (Feb. 2008);49(2):522-527.
Yurkovetskiy et al., Synthesis of a Macromolecular Camptothecin Conjugate with Dual Phase Drug Release. Mol Pharm. (2004) 1(5):375-382.
Zoller et al., “Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors”, Methods Enzymol. (1983) 100:468-500.
Zoller et al., “Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA”, Nucl Acids Res. (1982) 10(20):6487-6500.